Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

Jacobson IM;Lawitz E;Gane EJ;Willems BE;Ruane PJ;Nahass RG;Borgia SM;Shafran SD;Workowski KA;Pearlman B;Hyland RH;Stamm LM;Svarovskaia E;Dvory-Sobol H;Zhu Y;Subramanian GM;Brainard DM;McHutchison JG;Bräu N;Berg T;Agarwal K;Bhandari BR;Davis M;Feld JJ;Dore GJ;Stedman CAM;Thompson AJ;Asselah T;Roberts SK;Foster GR;;
gastroenterology 2017 Vol. 153 pp. -
253
im2017gastroenterologyefficacy

Abstract

In phase 3 trials of patients with HCV infection, we did not establish that sofosbuvir-velpatasvir-voxilaprevir for 8 weeks was noninferior to sofosbuvir-velpatasvir for 12 weeks, but the 2 regimens had similar rates of SVR in patients with HCV genotype 3 and cirrhosis. Mild gastrointestinal adverse …

Keywords

hepatitis c National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine adult female male adolescent aged middle aged young adult 80 and over Clinical Trial Phase III Randomized Controlled Trial Multicenter Study drug therapy combination antiviral agents / administration & dosage antiviral agents / therapeutic use* antiviral agents / adverse effects ira m jacobson chronic / drug therapy* sofosbuvir / administration & dosage sustained virologic response sulfonamides / therapeutic use* sulfonamides / adverse effects pmid:28390869 doi:10.1053/j.gastro.2017.03.047 eric lawitz graham r foster carbamates / administration & dosage carbamates / adverse effects carbamates / therapeutic use* heterocyclic compounds 4 or more rings / administration & dosage 4 or more rings / adverse effects 4 or more rings / therapeutic use* macrocyclic compounds / administration & dosage macrocyclic compounds / adverse effects macrocyclic compounds / therapeutic use* sofosbuvir / adverse effects sofosbuvir / therapeutic use* sulfonamides / administration & dosage

Access

URL:
http://www.ncbi.nlm.nih.gov/pubmed/28390869

Citation

ID: 268642
Ref Key: im2017gastroenterologyefficacy
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
268642
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store